Drivers of Epilepsy-related Cost of Care in an Integrated Healthcare System (P6.280)
Citation Manager Formats
Make Comment
See Comments

Abstract
Objective: Determine the factors associated with epilepsy-related care costs
Background: Drivers of epilepsy-related care costs have not been systematically studied
Design/Methods: We reviewed electronic medical records and cost data of epilepsy-treated patients between 2013–2016 from Partners Healthcare System’s Enterprise Data Warehouse. Total cost of care for epilepsy (TCC-E) was defined as sum of costs associated with all epilepsy-specific encounters (inpatient, outpatient, procedure, laboratory and hospital pharmacy) over 365 days. Changes in antiepileptic drug (AED) therapy, including additions/substitutions were assessed. Linear regression was used to model TCC-E; logistic regression modelled the likelihood of being in the top 5% and 1% of TCC-E. All models adjusted for demographic factors, insurance type, and neurologist access
Results: Data were available from 979 incident and 4392 prevalent cases. The mean and median TCC-E was $4768 and $602, respectively. TCC-E for incident cases was 104% higher than prevalent cases (p<0.001). Compared to focal seizures, total costs were 88% (p<0.001) higher for mixed seizures. Every additional Charlson Comorbidity Index (CCI) point was associated with 38% (p<0.001) higher, and psychiatric comorbidity with 159% (p<0.001) higher TCC-E. After controlling for AED generation(old vs new) and number of AEDs, calcium channel blockers (Pregabalin, Gabapentin, Ethosuximide) and SV2A binding agents (Levetiracetam) were associated with 64% and 98% higher TCC-E (p<0.001) compared to sodium channel blockers (Carbamazepine, Phenytoin, Fosphenytoin, Oxcarbazepine, Lacosamide, Lamotrigine). TCC-E was 88% higher for every additional AED change event; substitution and addition events were associated with 127% and 83% higher TCC-E (p<0.001). Incident status, comorbidities, and medication changes were significantly (p<0.05) associated with odds of being in top 5% and top 1% of TCC-E.
Conclusions: Epilepsy-related factors, comorbidities, and AED-related factors are significant predictors of TCC-E. Study limitations include cross-sectional design and non-inclusion of outpatient pharmacy costs
Study Supported by: UCB Pharma
Disclosure: Dr. Kakarmath has nothing to disclose. Dr. Agarwal has nothing to disclose. Dr. Golas has nothing to disclose. Dr. Felsted has nothing to disclose. Dr. Dye has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Yes. I am currently employed by UCB, Inc. since Jan 3, 2017 and formerly with Humana’s Comprehensive Health Insights for over 4 years. Dr. Dye has received personal compensation in an editorial capacity for Yes. I received a one-time compensation from the Journal of Managed Care Pharmacy for editorial review of manuscripts for a special edition. Dr. Fishman has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Yes, I am an employee of UCB, Inc. Dr. Levey has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Yes, I am an employee of UCB, Inc. Dr. Agboola has nothing to disclose.
Letters: Rapid online correspondence
REQUIREMENTS
If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Hemiplegic Migraine Associated With PRRT2 Variations A Clinical and Genetic Study
Dr. Robert Shapiro and Dr. Amynah Pradhan
Related Articles
- No related articles found.